Financial reports
10-K
2023 FY
Annual report
6 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
10-K
2022 FY
Annual report
22 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
31 Mar 22
Current reports
8-K
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7 Mar 24
8-K
Departure of Directors or Certain Officers
30 Jan 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
8-K
Entry into a Material Definitive Agreement
29 Sep 23
8-K
Termination of a Material Definitive Agreement
27 Sep 23
8-K
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
26 Sep 23
8-K
Departure of Directors or Certain Officers
16 Aug 23
8-K
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8 Aug 23
8-K
Regulation FD Disclosure
10 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
26 May 23
Registration and prospectus
S-8
Registration of securities for employees
31 Jan 24
S-8
Registration of securities for employees
17 Jan 24
S-3ASR
Automatic shelf registration
2 Jan 24
S-3
Shelf registration
20 Oct 23
D
$59.99 mm in equity / options / securities to be acquired, sold $59.99 mm, 14 investors
4 Oct 23
424B5
Prospectus supplement for primary offering
29 Sep 23
FWP
Free writing prospectus
28 Sep 23
FWP
Free writing prospectus
28 Sep 23
S-3MEF
Registration of additional securities for an S-3
27 Sep 23
424B5
Prospectus supplement for primary offering
27 Sep 23
Proxies
DEF 14A
Definitive proxy
14 Apr 23
PRE 14A
Preliminary proxy
4 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 22
DEF 14A
Definitive proxy
21 Apr 22
DEF 14A
Definitive proxy
21 Apr 21
DEF 14A
Definitive proxy
19 Oct 20
PRE 14A
Preliminary proxy
2 Oct 20
DEF 14A
Definitive proxy
20 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Apr 19
DEF 14A
Definitive proxy
29 Apr 19
Other
EFFECT
Notice of effectiveness
1 Nov 23
CORRESP
Correspondence with SEC
27 Oct 23
UPLOAD
Letter from SEC
27 Oct 23
EFFECT
Notice of effectiveness
3 Aug 23
CORRESP
Correspondence with SEC
31 Jul 23
UPLOAD
Letter from SEC
28 Jul 23
EFFECT
Notice of effectiveness
10 Feb 21
CORRESP
Correspondence with SEC
5 Feb 21
CORRESP
Correspondence with SEC
2 Feb 21
UPLOAD
Letter from SEC
28 Jan 21
Ownership
4
Kristen Yen
3 Apr 24
4
James H Mackaness
3 Apr 24
4
Patricia C Hirano
3 Apr 24
4
Bhatnagar Anish
3 Apr 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
4
Kristen Yen
29 Jan 24
4
Patricia C Hirano
29 Jan 24